Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 867

Results For "IT"

10284 News Found

Drugs Controller clears Covaxin, Corbevax and ZyCov-D for kids
News | April 26, 2022

Drugs Controller clears Covaxin, Corbevax and ZyCov-D for kids

The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)


USFDA approves first Covid-19 treatment for young children
Drug Approval | April 26, 2022

USFDA approves first Covid-19 treatment for young children

This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age


SRL Diagnostics opens state-of-the-art laboratory in Jamshedpur
Clinical Trials | April 26, 2022

SRL Diagnostics opens state-of-the-art laboratory in Jamshedpur

The new lab in the industrial town is SRL’s 4th lab in the state of Jharkhand


Differentiation based on innovation is the way forward: S Aparna
News | April 26, 2022

Differentiation based on innovation is the way forward: S Aparna

Secretary, Department of Pharmaceuticals and Union Health Secretary Chair a Panel Discussion on the theme 'Indian Pharma Vision 2047'


Corbevax gets DCGI nod for Emergency Use in 5-12 years
Drug Approval | April 26, 2022

Corbevax gets DCGI nod for Emergency Use in 5-12 years

The approval comes soon after Corbevax was given the nod for 12-15-year group


DCGI grants Covaxin Emergency Use Approval for children 6-12 years
Drug Approval | April 26, 2022

DCGI grants Covaxin Emergency Use Approval for children 6-12 years

Covaxin was earlier approved for children 12-18 years of age


ZyCoV-D two-dose vaccine receives Emergency Use Approval from DCGI
Drug Approval | April 26, 2022

ZyCoV-D two-dose vaccine receives Emergency Use Approval from DCGI

The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age


Shionogi’s once-a-day Covid-19 anti-viral shows rapid virus clearance
Biotech | April 25, 2022

Shionogi’s once-a-day Covid-19 anti-viral shows rapid virus clearance

A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year


‘DREAM-ND’ and ‘DREAM-D’ Phase 3 trials of Desidustat published in American Journal of Nephrology
Biotech | April 25, 2022

‘DREAM-ND’ and ‘DREAM-D’ Phase 3 trials of Desidustat published in American Journal of Nephrology

Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia


Glamyo Health records ARR of US $ 8 million last fiscal
Startup | April 25, 2022

Glamyo Health records ARR of US $ 8 million last fiscal

It is a multi-speciality healthcare brand which delivers a hassle-free experience for all types of cosmetic procedures and elective surgeries with personalized care